Delta Asset Management LLC TN Has $1.34 Million Stake in Pfizer Inc. (NYSE:PFE)

Delta Asset Management LLC TN lifted its stake in shares of Pfizer Inc. (NYSE:PFEFree Report) by 5.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 40,418 shares of the biopharmaceutical company’s stock after purchasing an additional 2,254 shares during the period. Delta Asset Management LLC TN’s holdings in Pfizer were worth $1,341,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Quinn Opportunity Partners LLC acquired a new position in Pfizer during the second quarter worth $10,304,000. Fulton Bank N.A. lifted its position in shares of Pfizer by 4.7% in the 3rd quarter. Fulton Bank N.A. now owns 176,239 shares of the biopharmaceutical company’s stock worth $5,846,000 after purchasing an additional 7,991 shares during the period. Portside Wealth Group LLC bought a new stake in shares of Pfizer in the 2nd quarter valued at $2,072,000. Brookstone Capital Management increased its stake in shares of Pfizer by 88.5% in the 3rd quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after acquiring an additional 212,369 shares in the last quarter. Finally, ETF Store Inc. increased its stake in Pfizer by 12.0% during the 3rd quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 727 shares in the last quarter. 68.05% of the stock is owned by institutional investors.

Pfizer Trading Down 0.0 %

PFE stock traded down $0.01 on Friday, reaching $27.56. The company’s stock had a trading volume of 28,838,118 shares, compared to its average volume of 45,460,027. The business has a fifty day simple moving average of $28.22 and a two-hundred day simple moving average of $31.51. Pfizer Inc. has a 12-month low of $25.76 and a 12-month high of $44.20. The firm has a market cap of $155.62 billion, a PE ratio of 76.53, a PEG ratio of 1.22 and a beta of 0.62. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.05 and a current ratio of 2.38.

Pfizer (NYSE:PFEGet Free Report) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.61% and a net margin of 3.62%. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter last year, the firm posted $1.14 earnings per share. The firm’s revenue was down 41.3% on a year-over-year basis. As a group, research analysts forecast that Pfizer Inc. will post 2.23 EPS for the current year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 1st. Investors of record on Friday, January 26th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.10%. This is an increase from Pfizer’s previous quarterly dividend of $0.41. The ex-dividend date is Thursday, January 25th. Pfizer’s dividend payout ratio (DPR) is presently 466.67%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Barclays cut their price objective on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a report on Thursday, December 14th. UBS Group cut their price target on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a report on Thursday, December 14th. Wells Fargo & Company cut their price target on shares of Pfizer from $39.00 to $35.00 and set an “equal weight” rating on the stock in a report on Monday, October 16th. JPMorgan Chase & Co. cut their price target on shares of Pfizer from $36.00 to $34.00 and set a “neutral” rating on the stock in a report on Monday, October 16th. Finally, Citigroup cut their price target on shares of Pfizer from $42.00 to $35.00 and set a “neutral” rating on the stock in a report on Monday, October 16th. Eleven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $36.93.

Read Our Latest Report on Pfizer

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb purchased 3,000 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were bought at an average cost of $26.47 per share, with a total value of $79,410.00. Following the acquisition, the director now owns 9,000 shares in the company, valued at $238,230. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.05% of the stock is owned by corporate insiders.

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.